Bioblast Pharma

Hope should not be rare

Chaime Orlev

Chaime Orlev

Chaime Orlev

CFO and VP Finance & Administration

Chaime Orlev joined Bioblast in September 2016. Prior to Bioblast, between 2011 to 2016, Mr. Orlev was Vice President, Finance and Administration in Chiasma (NASDAQ: CHMA), a biopharma company focused on improving the lives of patients with rare diseases, where he was instrumental in Chiasma’s multiple fund raising rounds and in taking the company through its successful IPO. Prior to Chiasma, he was a financial consultant to several Israeli biotechnology and medical device companies from 2008 to 2010. From 2008 to 2009, Mr. Orlev served as Chief Financial Officer of Oramed Pharmaceuticals Inc (NASDAQ: ORMP). Mr. Orlev received his M.B.A. from the Leon Recanati Graduate School of Business Administration at the Tel Aviv University and a B.A. in Business Administration from the College of Business in Israel. Mr. Orlev is a Certified Public Accountant under the laws of Israel.